| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1045392685 |
| P356 | DOI | 10.1007/S00256-014-1903-9 |
| P698 | PubMed publication ID | 24841276 |
| P5875 | ResearchGate publication ID | 262538625 |
| P2093 | author name string | Shuang Hu | |
| Guohua Shen | |||
| Zhiyun Jia | |||
| Houfu Deng | |||
| P2860 | cites work | The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews | Q24801517 |
| Cancer statistics, 2012 | Q27860574 | ||
| Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer | Q31866871 | ||
| Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. | Q33235606 | ||
| Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases | Q33705719 | ||
| Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data | Q33710688 | ||
| The role of positron emission tomography in the management of bone metastases | Q33970482 | ||
| Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. | Q34515936 | ||
| Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy | Q34917071 | ||
| Radionuclide bone imaging: an illustrative review | Q35086182 | ||
| Baseline staging of newly diagnosed prostate cancer: a summary of the literature | Q35764382 | ||
| Positron emission tomography and bone metastases | Q36070129 | ||
| The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer | Q36153503 | ||
| Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone | Q36159687 | ||
| Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. | Q36896858 | ||
| Prostate cancer: role of SPECT and PET in imaging bone metastases | Q37607846 | ||
| A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer | Q37760058 | ||
| Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. | Q38049420 | ||
| Conventional treatments of localized prostate cancer. | Q39309494 | ||
| Bone marrow imaging | Q39515738 | ||
| Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma | Q39530919 | ||
| Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study | Q40094312 | ||
| Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent | Q40612578 | ||
| Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model | Q41465470 | ||
| Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. | Q43026697 | ||
| FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. | Q43707212 | ||
| Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients | Q44639914 | ||
| [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy | Q45330298 | ||
| Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. | Q45959752 | ||
| The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. | Q46072225 | ||
| Bone metastasis in patients with non-small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. | Q46088590 | ||
| 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy | Q46586622 | ||
| A definition of molecular imaging. | Q50992977 | ||
| Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. | Q51809832 | ||
| Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? | Q53173525 | ||
| Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. | Q53186388 | ||
| Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. | Q53215000 | ||
| ¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. | Q53270927 | ||
| Molecular imaging of prostate cancer. | Q53359744 | ||
| Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. | Q53421961 | ||
| The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. | Q53553364 | ||
| Does Magnetic Resonance Imaging of the Spine Have a Role in the Staging of Prostate Cancer? | Q57694454 | ||
| Distribution of bony metastases in prostatic carcinoma | Q68578371 | ||
| Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose | Q70956697 | ||
| Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? | Q71197632 | ||
| Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases | Q72640926 | ||
| Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group | Q73570669 | ||
| The role of bone SPET study in diagnosis of single vertebral metastases | Q73790943 | ||
| Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET | Q74019866 | ||
| Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain | Q74625722 | ||
| Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer | Q78024622 | ||
| Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases | Q81834340 | ||
| Fluorine-18 deoxyglucose Positron Emission Tomography, Magnetic Resonance Imaging and Bone Scintigraphy for the Diagnosis of Bone Metastases in Patients with Lung Cancer: Which One is the Best? – a Meta-analysis | Q82537121 | ||
| Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) | Q84596973 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| bone scintigraphy | Q1928938 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 1503-1513 | |
| P577 | publication date | 2014-05-20 | |
| P1433 | published in | Skeletal Radiology | Q7534365 |
| P1476 | title | Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis | |
| P478 | volume | 43 |
| Q47693515 | (68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. |
| Q38823661 | A urologist's perspective on prostate cancer imaging: past, present, and future |
| Q90142774 | Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride |
| Q92253913 | Bone Metastasis: Current State of Play |
| Q28071705 | Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology |
| Q30241244 | CCAFU french national guidelines 2016-2018 on prostate cancer |
| Q55601670 | Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis. |
| Q89980619 | Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France |
| Q64912188 | Comparison of diagnostic value of multi-slice spiral CT and MRI for different pathological stages of prostate cancer. |
| Q38639486 | Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. |
| Q64030381 | Consensus on molecular imaging and theranostics in prostate cancer |
| Q48167919 | Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology |
| Q93271818 | Cost-consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer |
| Q47759996 | Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. |
| Q53682227 | Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. |
| Q26777520 | Diagnostic Performance of Diffusion-weighted Magnetic Resonance Imaging in Bone Malignancy: Evidence From a Meta-Analysis |
| Q41563753 | Diagnostic performance of 11C-choline PET/CT and bone scintigraphy in the detection of bone metastases in patients with prostate cancer |
| Q57106260 | Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis |
| Q41869736 | Diagnostic role of (99)Tc(m)-MDP SPECT/CT combined SPECT/MRI Multi modality imaging for early and atypical bone metastases |
| Q92382857 | Diagnostic value and clinical significance of MRI and CT in detecting lymph node metastasis of early cervical cancer |
| Q60955512 | Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer |
| Q58005202 | Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysis |
| Q92802105 | Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study |
| Q48105677 | Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort |
| Q36652042 | Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria |
| Q55492615 | Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging. |
| Q39123279 | Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience. |
| Q53734447 | Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). |
| Q38269763 | Evolving role of positron emission tomography (PET) in urological malignancy |
| Q90039937 | False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography |
| Q57107850 | Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer |
| Q89823517 | Imaging for Metastasis in Prostate Cancer: A Review of the Literature |
| Q57105949 | Imaging of distant metastases of prostate cancer |
| Q58092281 | Impact of sodium F-fluoride PET/CT, F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study |
| Q33776371 | Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. |
| Q31108842 | METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. |
| Q38636446 | Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know |
| Q35879087 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. |
| Q64993061 | Multiparametric MRI - local staging of prostate cancer and beyond. |
| Q62839505 | Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors |
| Q64902379 | Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. |
| Q33836426 | PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models |
| Q31003607 | PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data |
| Q57780524 | PET/MRI and prostate cancer |
| Q51641159 | Patient-specific geometrical modeling of orthopedic structures with high efficiency and accuracy for finite element modeling and 3D printing. |
| Q36418328 | Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analysis |
| Q36078353 | Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design |
| Q57107208 | Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges |
| Q50027134 | Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review |
| Q58562169 | Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer |
| Q39155149 | Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team |
| Q58117324 | Targeted Nanomedicine to Treat Bone Metastasis |
| Q49589359 | The role of PSMA PET-CT in patients with metastatic prostate cancer |
| Q49981290 | The role of PSMA PET-CT in patients with metastatic prostate cancer |
| Q57299101 | Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group |
| Q47732077 | WB MRI and oncology: recent major advances. |
| Q53098000 | Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. |
| Q89481604 | Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review |
| Q58564104 | Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences |
| Q38802235 | Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. |
| Q60714624 | Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses |
| Q104517654 | [French ccAFU guidelines - update 2020-2022: prostate cancer] |
Search more.